A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting
Authors:
- Roque PifarreRPRoque Pifarre
- Hartzell V. SchaffHSHartzell V. Schaff
- Jan C. HorrowJHJan C. Horrow
- Robert AlbusRARobert Albus
- Bruce SpiessBSBruce Spiess
- Todd K. RosengartTRTodd K. Rosengart
- Jeffrey MurrayJMJeffrey Murray
- Richard E. ClarkRCRichard E. Clark
- Peter SmithPSPeter Smith
- Andrea NadelANAndrea Nadel
- Sharon L. BonneySBSharon L. Bonney
- 15 October 1995
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 92 (8) , 2236-2244
Abstract
Background Aprotinin is a serine protease inhibitor that reduces blood loss and transfusion requirements when administered prophylactically to cardiac surgical patients. To examine the safety and dose-related efficacy of aprotinin, a prospective, multicenter, placebo-controlled trial was conducted in patients undergoing repeat coronary artery bypass graft (CABG) surgery. Methods and Results Two hundred eighty-seven patients were randomly assigned to receive either high-dose aprotinin, low-dose aprotinin, pump-prime-only aprotinin, or placebo. Drug efficacy was determined by the reduction in donor-blood transfusion up to postoperative day 12 and in postoperative thoracic-drainage volume. The percentage of patients requiring donor–red-blood-cell (RBC) transfusions in the high- and low-dose aprotinin groups was reduced compared with the pump-prime-only and placebo groups (high-dose aprotinin, 54%; low-dose aprotinin, 46%; pump-prime only, 72%; and placebo, 75%; overall P =.001). The number of units of donor RBCs transfused was significantly lower in the aprotinin-treated patients compared with placebo (high-dose aprotinin, 1.6±0.2 U; low-dose aprotinin, 1.6±0.3 U; pump-prime-only, 2.5±0.3 U; and placebo, 3.4±0.5 U; P =.0001). There was also a significant difference in total blood-product exposures among treatment groups (high-dose aprotinin, 2.2±0.4 U; low-dose aprotinin, 3.4±0.9 U; pump-prime-only, 5.1±0.9 U; placebo, 10.3±1.4 U). There were no differences among treatment groups for the incidence of perioperative myocardial infarction (MI). Conclusions This study demonstrates that high- and low-dose aprotinin significantly reduces the requirement for donor-blood transfusion in repeat CABG patients without increasing the risk for perioperative MI.Keywords
This publication has 50 references indexed in Scilit:
- Activated Clotting Time, Anticoagulation, Use of Heparin, and Thrombin Activation during Extra-corporeal Circulation: Changes under Aprotinin TherapyThe Thoracic and Cardiovascular Surgeon, 1993
- The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurementBlood Coagulation & Fibrinolysis, 1993
- APROTININ TREATMENT IN CARDIAC SURGERYAnesthesiology, 1992
- A Trial of Desmopressin (1-Desamino-8-D-Arginine Vasopressin) to Reduce Blood Loss in Uncomplicated Cardiac SurgeryNew England Journal of Medicine, 1989
- Bleeding after Cardiopulmonary BypassNew England Journal of Medicine, 1986
- Treatment with Desmopressin Acetate to Reduce Blood Loss after Cardiac SurgeryNew England Journal of Medicine, 1986
- An Improved Technique for Autotransfusion of Shed Mediastinal BloodThe Annals of Thoracic Surgery, 1985
- Clinical Application of Inhibitors of FibrinolysisDrugs, 1985
- Early Results and Complications of Coronary Artery Bypass Surgery: A Consecutive Series of 441 PatientsScandinavian Journal of Thoracic and Cardiovascular Surgery, 1985
- The effect of aprotinin (a serine protease inhibitor) on renal function and renin release.Hypertension, 1983